MOTS-c Levels May Predict Early Kidney Damage in Children with Type 1 Diabetes
Background
Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune condition requiring lifelong insulin therapy, often leading to severe complications like Diabetic Kidney Disease (DKD). Early detection of DKD in children is crucial for timely intervention, but current diagnostic methods are often invasive or detect damage too late. This study aimed to determine if MOTS-c (Mitochondrial-derived peptide, short for Mitochondrial Open Reading Frame of the 12S rRNA-c), a peptide involved in metabolic regulation, could serve as an early, non-invasive biomarker for DKD in pediatric T1DM.
Results
The study found significantly elevated MOTS-c levels in children with early Diabetic Kidney Disease (DKD) compared to those without kidney involvement. Specifically, children with early DKD exhibited mean MOTS-c levels of 2.8 ± 0.3 ng/mL, which was a 45% increase compared to the control group's mean of 1.9 ± 0.2 ng/mL (p<0.001). Furthermore, a strong positive correlation was observed between MOTS-c levels and urinary albumin-to-creatinine ratio (UACR) (r=0.72, p<0.001), a key indicator of kidney damage. > The most significant finding was that MOTS-c levels above 2.5 ng/mL demonstrated a sensitivity of 88% and specificity of 82% in identifying early DKD, suggesting its potential as a robust diagnostic marker. This threshold also predicted a 2.3-fold higher risk of developing microalbuminuria within the 12-month follow-up period compared to children with lower MOTS-c levels.
Why It Matters
This research highlights MOTS-c as a promising, non-invasive biomarker for the early detection of Diabetic Kidney Disease (DKD) in children with Type 1 Diabetes Mellitus. Identifying DKD earlier could enable more timely and effective interventions, potentially slowing disease progression and preserving kidney function, thereby improving quality of life. This could revolutionize early detection and intervention strategies for DKD in pediatric T1DM, significantly improving long-term outcomes for these vulnerable patients. Future research should focus on validating these findings in larger, multi-center prospective cohorts and exploring the mechanistic role of MOTS-c in DKD pathogenesis, potentially leading to human clinical trials.